E
Eleanor I Ager
Researcher at University of Melbourne
Publications - 25
Citations - 1466
Eleanor I Ager is an academic researcher from University of Melbourne. The author has contributed to research in topics: Genomic imprinting & Cancer. The author has an hindex of 17, co-authored 25 publications receiving 1283 citations. Previous affiliations of Eleanor I Ager include University of Western Australia & Harvard University.
Papers
More filters
Journal ArticleDOI
The renin-angiotensin system and malignancy.
TL;DR: The renin-angiotensin system is a target for cancer treatment and the suggested underlying mechanisms of its paracrine effects are reviewed, which include modulation of angiogenesis, cellular proliferation, immune responses and extracellular matrix formation.
Journal ArticleDOI
Analysis of the platypus genome suggests a transposon origin for mammalian imprinting
Andrew J Pask,Andrew J Pask,Anthony T. Papenfuss,Eleanor I Ager,Kaighin A. McColl,Terence P. Speed,Marilyn B. Renfree +6 more
TL;DR: Comparisons between prototherian and therian mammals provide strong support for the host defence hypothesis and show that the platypus has significantly fewer repeats of certain classes in the regions of the genome that have become imprinted in therian mammal.
Journal ArticleDOI
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
David P. Kodack,Euiheon Chung,Hiroshi Yamashita,Joao Incio,Annique M M J Duyverman,Youngchul Song,Christian T. Farrar,Yuhui Huang,Eleanor I Ager,Walid S. Kamoun,Shom Goel,Matija Snuderl,Alisha Lussiez,Lotte Hiddingh,Sidra Mahmood,Bakhos A. Tannous,April F. Eichler,Dai Fukumura,Jeffrey A. Engelman,Rakesh K. Jain +19 more
TL;DR: It is observed that the combination of a HER2 inhibitor with an anti–VEGF receptor-2 (VEGFR2) antibody significantly slows tumor growth in the brain, resulting in a striking survival benefit, and clinical development of this three-drug regimen for the treatment of HER2-amplified breast cancer brain metastases is supported.
Journal ArticleDOI
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
Eleanor I Ager,Sergey V. Kozin,Nathaniel D. Kirkpatrick,Giorgio Seano,David P. Kodack,Vasileios Askoxylakis,Yuhui Huang,Shom Goel,Matija Snuderl,Alona Muzikansky,Dianne M. Finkelstein,Daniel T. Dransfield,Laetitia Devy,Yves Boucher,Dai Fukumura,Rakesh K. Jain +15 more
TL;DR: MMP14 blockade decreased immunosuppressive TGFβ, polarized macrophages to an antitumor phenotype, increased iNOS, and improved tumor perfusion, resulting in reduced primary tumor growth and enhanced response to radiation therapy, especially in high MMP14-expressing tumors.
Journal ArticleDOI
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression
Shom Goel,Nisha Gupta,Brian P. Walcott,Matija Snuderl,Cristina T. Kesler,Nathaniel D. Kirkpatrick,Takahiro Heishi,Yuhui Huang,John D. Martin,Eleanor I Ager,Rekha Samuel,Shuhan Wang,John Yazbek,Benjamin J. Vakoc,Randall T. Peterson,Timothy P. Padera,Dan G. Duda,Dai Fukumura,Rakesh K. Jain +18 more
TL;DR: It is demonstrated that pharmacological VE-PTP inhibition can normalize the structure and function of tumor vessels through Tie-2 activation, which delays tumor growth, slows metastatic progression, and enhances response to concomitant cytotoxic treatments.